December 1, 2008. BiOptix Unveils Label-free, Highly-sensitive Microarray BioAnalyzer, Schedules a Demosntration (Booth 737) and a Press Conference at 2009 PittCon on March 8-13, 2009.

print back

Contact: Misha Plam,
CEO,
BiOptix LLC
(303) 641-3669
m.plam@comcast.net
http://www.BiOptix.com

Boulder, Colorado, December 1, 2008.

BOULDER, CO, December 1, 2008 /PRNewswire/ - BiOptix, Inc. has unveiled a best-in-class commercially available microarray bio-analyzer, model 207B, which incorporates novel, highly-sensitive and label-free technology invented by John Hall, 2005 Nobel Prize Laureate, yielding reliable and real-time molecular interaction detection and measurement of kinetic constants capabilities. The BiOptix 207B has demonstrated sensitivity 10 times greater than the current commercially available competing technologies while additionally enabling superior fixed and expandable multiplexing capabilities compared to competitive offerings.

The BiOptix 207B sensor array format enables simultaneous affinity measurements of a diverse array of analytes such as oligonucleotides, antibodies, bacteria, viruses, glycans and other proteins as well as identification and correction of bulk and non-specific binding effects delivered with industry leading sensitivity. Applications for the BiOptix 207B include pharmaceutical quality control, research and development, biotherapeutic drug discovery, rapid point-of-care diagnostics, and environmental monitoring. The instrument features a small footprint, low power consumption, and user-friendly interface.

Live demonstration of the biodetector will take place in Booth 737 at the March 8-13, 2009 PittCon conference in Chicago. A press conference introducing the new instrument will be held during the conference in room Room S105A on March 9, 2009 from 10:30 AM to 11:00AM.

About: BiOptix develops ultra-sensitive biosensors for detection of clinically significant trace amounts of biological and chemical agents in real-time and with minimal human intervention. The biosensor design relies upon the common path interferometric detection principle in combination with non-resonant surface plasmon excitation. This design was conceived by BiO

Link to the original press release